[Expression of NFkappaB p65 and its target genes in gastric cancer and precancerous lesions].
OBJECTIVE
To study the expression of NFkappaB p65 and its target genes in intestinal metaplasia (IM), dysplasia (Dys), gastric cancer (GC) infected with Helicobacter pylori (Hp) and explore the mechanism of infection by cytotoxin-associated antigen A expressing Hp (CagA(+)Hp) in the development of gastric cancer.


METHODS
CagA antibody in blood sample of 289 patients was determined by ELISA. Hp was detected by rapid urease test and Warthin starry staining. Expression of NFkappaB p65 and its target genes in IM, Dys and GC was examined by immunohistochemistry.


RESULTS
In IMI approximately II, IMIII, DysI, DysII approximately III and GC, the expression of NFkappaB p65 was significantly higher in patients with CagA(+)Hp infection than those without CagA Hp infection. In IMIII and DysII approximately III, the expression of NFkappaB p65, c-myc, CyclinD(1) and bcl-xl was significantly higher in patients with CagA Hp infection than those without CagA Hp infection. In gastric cancer infected with CagA(+)Hp, the expression of NFkappaB p65, c-myc, CyclinD(1) and bcl-xl was significantly higher in intestinal type than in diffuse type.


CONCLUSIONS
There are different mechanisms in intestinal type and diffuse type in the development of gastric cancer. The occurrence of intestinal type gastric cancer is associated with CagA(+)Hp infection which by NFkappaB p65 upregulating the expression of c-myc, CyclinD(1),bcl-xl in patients with IMIII, DysII approximately III. It may be an effective method to prevent gastric cancer by inhibiting NFkappaB p65.
Yang
Gui-fang
GF
Department of Pathology, Zhongnan Hospital Wuhan University, Wuhan 430071, China.
Deng
Chang-sheng
CS
Xiong
Yong-yan
YY
Luo
Jun
J
Wang
Bi-cheng
BC
Tian
Su-fang
SF
Xu
Ke
K
D000328:Adult; D000368:Aged; D000942:Antigens, Bacterial / Q000032:analysis; D001426:Bacterial Proteins / Q000032:analysis; D019938:Cyclin D1 / Q000378:metabolism; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000378:metabolism* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D011230:Precancerous Conditions / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D013274:Stomach Neoplasms / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D051996:Transcription Factor RelA / Q000235:genetics / Q000378:metabolism*; D051020:bcl-X Protein / Q000378:metabolism
D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D016271:Proto-Oncogene Proteins c-myc; D051996:Transcription Factor RelA; D051020:bcl-X Protein; C080866:cagA protein, Helicobacter pylori; D019938:Cyclin D1